ELISA kits for the measurment of SDF-1/CXCL12
SDF-1α (CXCL12) is a CXC chemokine. The small basic protein (ca. 8 kDa) has no glycosylation site in its sequence. The homology properties of SDF-1α are unique among the chemokines more
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
SDF-1α (CXCL12) is a CXC chemokine. The small basic protein (ca. 8 kDa) has no glycosylation site in its sequence. The homology properties of SDF-1α are unique among the chemokines more
Europeans live longer and healthier lives than in the past, partly due to successful environmental policies that have reduced the exposure to harmful environmental contaminants in air, water and food, according to a new report. However, these contaminants are still a problem, and several new health more
Patients with advanced kidney disease who are undergoing hemodialysis are known to be highly susceptible to heart attacks and other cardiovascular complications, and now scientists likely know why. New research findings published in the Journal of Leukocyte Biology show that uremic toxins, which are more
Many diseases are caused by malfunction of the mTOR signaling network. Accurate knowledge of network protagonists could therefore provide new therapeutic targets. The research group of Prof. Michael N. Hall at the Biozentrum of the University of Basel has now identified a number of new mTOR-regulate more
Up until the new millennium, the pharmaceutical industry grew stronger by 11%. However, the blockbuster model is increasingly at risk and the declining growth rates in the industry require a search for new strategies. In this context, orphan drugs are becoming increasingly important more
Hypertension is a modifiable risk factor for cardiovascular disease. Lowering blood pressure (BP) reduces cardiovascular risk; yet despite the availability of numerous antihypertensives, the proportion of patients achieving BP control remains low. Treatment guidelines are based on evidence from clin more
Statins are the most widely used group of lipid-lowering drugs and they have been shown to be effective in the prevention of cardiovascular disease, primarily by reducing plasma low-density lipoprotein cholesterol concentrations and possibly through other pleiotropic effects. However, there are larg more
l‐Arginine (l‐Arg) is a conditionally essential amino acid in the human diet. The most common dietary sources of l‐Arg are meat, poultry and fish. l‐Arg is the precursor for the synthesis of nitric oxide (NO); a key signaling molecule via NO synthase (NOS). Endogenous NOS inhibitors such as asymme more
TechNavio’s analysts forecast the Drug-eluting Stent market in Europe to grow at a CAGR of 4.3 percent over the period 2011–2015. One of the key factors contributing to this market growth is the high prevalence of cardiovascular diseases in the region. The Drug-eluting Stent market in Europe has als more
TechNavio’s analysts forecast the Global Implantable Cardioverter Defibrillator (ICD) market to reach US$6.22 billion by 2015. One of the key factors contributing to this market growth is the rising incidence of Cardiovascular diseases. The Global ICD market has also been witnessing the development more
TechNavio's analysts forecast the Global Bare Metal Stents market to reach US$1.86 billion by 2015. One of the key factors contributing to this market growth is the high prevalence of cardiovascular diseases. The Global Bare Metal Stents market has also been witnessing the trend of increasing demand more
Quintiles Clinical Commercial Consulting Capital Therapeutic Areas Careers Browse Information Library Start your search by selecting a topic or browse content in all topics Therapeutic Areas Business Needs Perspectives Services Locations Cardiovascular Central Nervous System (CNS) Diabetes more
Careers News and Events Investors PAREXEL CHAIRMAN AND CEO NAMED EXECUTIVE OF THE YEAR IN NORTH AMERICA IN INTERN... PAREXEL EXPERTS TO PRESENT INSIGHTS INTO SUCCESSFUL GLOBAL PRODUCT DEVELOPMENT ... PAREXEL ANNOUNCES DATE OF FOURTH QUARTER AND FISCAL YEAR 2010 EARNINGS RELEASE A... PAREXEL CONS more
Home page Add Bookmark ? About Us Our Products Real Time Real Time PCR Kits HIV and HIV Associated Infections Kits Hepatitis Viruses Kits Human Papilloma Viruses Kits Sexually Transmitted Infections Kits Herpes Viruses Kits TORCH Complex Kits Respiratory Infections Kits Neurological Infections Kits more
Watchlist
This is where you can add this topic to your personal favourites